Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

NCT02158520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Mucosal Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IV Uveal Melanoma AJCC v7
Unresectable Melanoma

Interventions

BIOLOGICAL: Bevacizumab
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
DRUG: Nab-paclitaxel
OTHER: Pharmacological Study

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]